

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property  
Organization  
International Bureau



(43) International Publication Date  
15 January 2004 (15.01.2004)

PCT

(10) International Publication Number  
WO 2004/004726 A1

(51) International Patent Classification<sup>7</sup>: A61K 31/47,  
C07D 215/38, 409/12, 401/12, 407/12, A61K 31/4709,  
A61P 3/04, 25/00

(21) International Application Number:  
PCT/GB2003/002884

(22) International Filing Date: 4 July 2003 (04.07.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:  
0202134-3 8 July 2002 (08.07.2002) SE

(71) Applicant (for AE, AG, AL, AM, AT, AU, AZ, BA, BB, BE, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CY, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, FR, GB, GD, GE, GH, GM, GR, HR, HU, ID, IE, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, SZ, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW only): ASTRAZENECA AB [SE/SE]; Sodertalje, S-151 85 (SE).

(71) Applicant (for MG only): ASTRAZENECA UK LIMITED [GB/GB]; 15 Stanhope Gate, London, Greater London W1K 1LN (GB).

(72) Inventors; and


(75) Inventors/Applicants (for US only): RAY, Asim, Kumar [IN/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). SIGFRIDSSON, Emma, Margareta [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). LINUSSON, Anna, Stina, Maria [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). SANDBERG, Pernilla, Marie [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). INGARDT, Tord [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). SVENSSON, Anette, Marie [SE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE). BRICKMANN, Kay [DE/SE]; AstraZeneca R & D Mölndal, S-431 83 Mölndal (SE).

(74) Agent: ASTRAZENECA; Global Intellectual Property, Mereside, Alderley Park, Macclesfield, Cheshire SK10 4TG (GB).

(81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: MCHIR ANTAGONISTS



(57) Abstract: The present invention provides compounds of formula (I), wherein R<sup>1</sup> represents a C<sub>1-4</sub>alkoxy group optionally substituted by one or more fluoro or a C<sub>1-4</sub>alkyl group optionally substituted by one or more fluoro; n represents 0 or 1; R<sup>2</sup> represents a C<sub>1-4</sub>alkyl group optionally substituted by one or more fluoro or a C<sub>1-4</sub>alkoxy group optionally substituted by one or more fluoro; m represents 0 or 1; R<sup>3</sup> represents H or a C<sub>1-4</sub>alkyl group; L<sup>1</sup> represents an alkylene chain (CH<sub>2</sub>)<sub>r</sub> in which r represents 2 or 3 or L<sup>1</sup> represents a cyclohexyl group wherein the two nitrogens bearing R<sup>3</sup> and R<sup>4</sup>, respectively, are linked to the cyclohexyl group via the 1,3 position of the cyclohexyl group and additionally when R<sup>5</sup> represents 9, 10-methanoanthracen-9(10H)-yl the group -L<sup>1</sup>-N(R<sup>4</sup>)- together represents a piperidyl ring which is linked to L<sup>2</sup> through the piperidyl nitrogen and to N-R<sup>3</sup> via the 4 position of the piperidyl ring with the proviso that when R<sup>5</sup> represents 9, 10-methanoanthracen-9(10H)-yl then r is only 2; R<sup>4</sup> represents H or a C<sub>1-4</sub>alkyl group optionally substituted by one or more of the following: an aryl group or a heteroaryl group; L<sup>2</sup> represents a bond or an alkylene chain (CH<sub>2</sub>)<sub>s</sub> in which s represents 1, 2 or 3 wherein the alkylene chain is optionally substituted by one or more of the following: a C<sub>1-4</sub>alkyl group, phenyl or heteroaryl; R<sup>5</sup> represents aryl, a heterocyclic group or a C<sub>3-6</sub>cycloalkyl group which is optionally fused to a phenyl or to a heteroaryl group; as well as optical isomers and racemates thereof as well as pharmaceutically acceptable salts, thereof; with provisos, processes for preparing such compounds, their use in the treatment of obesity, psychiatric disorders, cognitive disorders, memory disorders, schizophrenia, epilepsy, and related conditions, and neurological disorders such as dementia, multiple sclerosis, Parkinson's disease, Huntington's chorea and Alzheimer's disease and pain related disorders and to pharmaceutical compositions containing them.

WO 2004/004726 A1